

<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)  <b>PTO Form 1449</b>		Attorney Docket No. 021390-004041		Application No.			
		Applicants: Bing-Yan ZHU <i>et al.</i>				<b>PAGE 1 of 3</b>	
		Filing Date: 10/15/2003		Group Art Unit: 1625			
<b>U.S. PATENT DOCUMENTS</b>							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
		4,514,416	April 30, 1985	Fujii et al.	549	442	
		4,971,957	November 20, 1990	Tsutsumi et al.	514	79	
		4,912,001	March 27, 1990	Kouno et al.	430	71	
		5,569,768	October 29, 1996	Boyd et al.	548	253	
		5,576,343	November 19, 1996	Nagahara et al.	514	422	
		5,872,115	February 16, 1999	Binet et al.	514	211	
ynd		6,140,351	October 31, 2000	Arnaiz et al.	514	336	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		John D. Young <i>et al.</i> , "Interannular Interactions in Para-Substituted Diphenylmethane Anion Radicals," <i>J. Am. Chem. Soc.</i> , 94:25, December 1972					
		Hitomi Suzuki <i>et al.</i> , "Selective Reduction with Lithium Aluminum Hydride/Diphosphorus Tetraiodide. A Mild Conversion of Aromatic Ketones to Parent Hydrocarbons," <i>Chemistry Letters</i> , pp. 909-910, 1983.					
		St. Goldschmidt and P. Modderman, "Biphenyl Derivatives II. Basic 4-Biphenyl Compounds," <i>Recueil</i> , 69, 1109-1117 (1950).					
		W. F. Cockburn <i>et al.</i> , "Molecular Rearrangement of Tertiary Amines. Part I," <i>J. Chem. Soc.</i> , No. 8, pp. 3340-3346 (1960).					
		Hamilton, A., "Intra- and Intermolecular Hydrogen Bonding Control of Supramolecular Structure," NATO ASI Ser., Ser. C. (Computational Approaches In Supramolecular Chemistry) Vol. 426, 101-8, (1994).					
		El-Nagdy, S., <i>Asian J. Chem.</i> 2(4):368-78 (1990).					
ynd		Kulkarni, <i>J. Indian Chem. Soc.</i> 61(8):720-1 (1984)					
Examiner <i>Lin N Davis</i>				Date Considered <i>4/29/2004</i>			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  <b>PTO Form 1449</b>	<b>Attorney Docket No.</b> 021390-004041	<b>Application No.</b>
	<b>Applicants:</b> Bing-Yan ZHU <i>et al.</i>	
	<b>Filing Date:</b> 10/15/2003	<b>Group Art Unit:</b> 1625

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date Day/Mo/Yr	Country	Class	Sub Class	Translation YES NO	
↑	540 051 A1	05/05/1993	EP				
	418,675	06/07/1992	JP (w/English Abstract)				X
	59-181257	15/10/1984	JP(w/English Abstract)				X
↓	11302177	02/11/1999	JP(w/English Abstract)				X

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

↑	Hey, D., <u>J. Chem. Soc.</u> 16, 1513-18 (1967).
↑	El-Zanfally, S., <u>Egypt. J. Pharm. Sci.</u> Vol. 17(1), 29-34 (1978).
↑	Bing-Yan Zhu et al., <u>Annual Reports in Medicinal Chemistry</u> , 35, pp. 83-102 (2000).

<b>Examiner</b> <i>Lena N Davis</i>	<b>Date Considered</b> 4/29/2004
--	-------------------------------------

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  <b>PTO Form 1449</b>	<b>Attorney Docket No.</b> 021390-004041	<b>Application No.</b> 
	<b>Applicants:</b> Bing-Yan ZHU <i>et al.</i>	
	<b>Filing Date:</b> 10/15/2003	<b>Group Art Unit:</b> 1625

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date Day/Mo/Yr	Country	Class	Sub Class	Translation	
						YES	NO
↑	96/28427	19 September 1996	WO				
	97/29067	14 August 1997	WO				
	98/06694	19 February 1998	WO				
	98/09630	12 March 1998	WO				
	98/28269	2 July 1998	WO				
	98/28282	2 July 1998	WO				
	98/57934	23 December 1998	WO				
	99/00121	7 January 1999	WO				
	99/00126	7 January 1999	WO				
	99/00127	7 January 1999	WO				
	99/00128	7 January 1999	WO				
	99/32477	1 July 1999	WO				
	00/34237	15 June 2000	WO				
	00/34238	15 June 2000	WO				
	00/34258	15 June 2000	WO				
	00/34260	15 June 2000	WO				
	00/34261	15 June 2000	WO				
	00/34268	15 June 2000	WO				
	00/34269	15 June 2000	WO				
	00/39118	6 July 2000	WO				

Examiner

*Line N Davis*

Date Considered

*4/29/2004*

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

1

of

1

**Complete If Known**

Application Number

10/687,334

Filing Date

10/15/2003

First Named Inventor

Bing-Yan Zhu

Art Unit

1625

Examiner Name

DAVLS

Attorney Docket Number

021390-004041

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
gnd	AA	WO	99/42439	A1	08/26/1999	Roche Diagnostics GmbH		<input type="checkbox"/>
								<input type="checkbox"/>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner  
Signature

Lynn N Davis

Date  
Considered

4/29/2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket No.:  
021390-004041

Application No.:

Applicants: Bing-Yan ZHU et al.

Filing Date: 10/25/2003

Group 1625

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub Class	Translation Yes No
md	0 937 711 A1	25 August 1999	Europe			X

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

md	Michael R. Wiley et al., "Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa: Evaluation of Selectively, Anticoagulant Activity, and Antithrombotic Activity", <u>J. Med. Chem.</u> , Vol. 43, pp. 883-899 (2000).
	Ying K. Yee et al., "N <sup>2</sup> -Aroylanthranilamide Inhibitors of Human Factor Xa", <u>J. Med. Chem.</u> , Vol. 43, pp. 873-882 (2000).
	David K. Herron et al., "1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa", <u>J. Med. Chem.</u> , Vol. 43, pp. 859-872 (2000).
	W. E. Bachmann et al., "Reduction by Magnesium + Magnesium Halide, XIII. The Reaction Between Epoxy Ketones and Grignard Reagents", <u>Journal of the American Chemical Society</u> , Vol. 56, No. 7, pp. 1559-1560 (1934).
	Takashi Keumi et al., "2-(Trifluoromethylsulfonyloxy)pyridine as a Reagent for the Ketone Synthesis from Carboxylic Acids and Aromatic Hydrocarbons", <u>Bull. Chem. Soc. Jpn.</u> , Vol. 61, No. 2, pp. 455-459 (1988).
	"Dictionary of Organic Compounds, 5th Ed., Vol. 5," Chapman and Hall, New York, NY, US (1982), compounds T-00160, T-00161, T-00162, p. 5119 (1982).
	Herbert J. Sipe, Jr. et al., "An Improved Synthesis of Aryl Sulfones", <u>Synthesis</u> , No. 3, pp. 283-284 (1984).
md	Richard Kuhn et al., "Addition von Maleinsäure-anhydrid an Polyene. (Über konjugierte Doppelbindungen, XIV." <u>Berichte Der Deutschen Chemischen Gesellschaft</u> , Vol. 63, pp. 2662-2679 (1930).

Examiner *Klaus N. Davis*

Date Considered

4/29/2004

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.